Lifecare (LIFE) Stock Overview
Operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LIFE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifecare ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.29 |
| 52 Week High | NOK 23.50 |
| 52 Week Low | NOK 0.27 |
| Beta | -0.43 |
| 1 Month Change | -27.25% |
| 3 Month Change | -27.16% |
| 1 Year Change | -95.39% |
| 3 Year Change | -98.82% |
| 5 Year Change | -99.22% |
| Change since IPO | -98.91% |
Recent News & Updates
Narrative Update • May 25
LIFE: Future Regulatory Clearance And Implant Longevity Results Will Support Repricing Potential
The analyst price target for Lifecare has been revised lower to NOK0.40 from NOK0.65, with analysts highlighting a reduced revenue growth outlook, a lower discount rate, a slightly higher profit margin assumption, and a much higher future P/E input in their updated valuation work. Analyst Commentary Analysts are reassessing Lifecare after the latest valuation update, and the revised inputs around growth, margins, discount rate, and future P/E are shaping both the optimistic and cautious views.Narrative Update • May 10
LIFE: Future Regulatory Clearance On CGM Implant Will Support Repricing Potential
Analysts have lifted their price target on Lifecare to NOK 0.65 per share, citing a slightly lower discount rate, a modestly higher forecast profit margin, and a reduced forward P/E assumption that together support a more efficient earnings profile at the same fair value level. Analyst Commentary Recent research commentary on Lifecare centers on how the revised price target aligns with updated assumptions for profitability, discount rates, and forward P/E.Narrative Update • Apr 20
LIFE: Future Regulatory Progress On CGM Implant Will Drive Repricing Potential
The analyst price target for Lifecare has been revised to reflect a steady fair value of NOK 0.65. This incorporates slightly updated assumptions for the discount rate, profit margin, and forward P/E, as analysts highlight supportive research on comparable tech-enabled insurance platforms and their large, underpenetrated markets.Narrative Update • Apr 04
LIFE: Future Regulatory Progress And Commercial Execution Will Drive Repricing Potential
Analysts have nudged up the Lifecare price target to NOK 0.65, citing a lower discount rate and slightly refined long term P/E assumptions while maintaining their fair value estimate. Analyst Commentary Analysts looking at Lifecare’s revised price target are framing it in the context of how similar high growth, tech enabled models in other parts of the health and insurance space are being valued.Narrative Update • Mar 20
LIFE: Future Regulatory And Clinical Milestones Will Drive Repricing Potential
The analyst price target for Lifecare has been raised by NOK 1, reflecting updated assumptions around a higher discount rate, more measured revenue growth at 51.30% and a slightly lower projected profit margin of 19.61%. The valuation still applies a forward P/E of 4.39x that analysts see as supported by improving unit economics and technology driven operating efficiencies similar to those recently highlighted across the life insurance peer group.Recent updates
Narrative Update • May 25
LIFE: Future Regulatory Clearance And Implant Longevity Results Will Support Repricing Potential
The analyst price target for Lifecare has been revised lower to NOK0.40 from NOK0.65, with analysts highlighting a reduced revenue growth outlook, a lower discount rate, a slightly higher profit margin assumption, and a much higher future P/E input in their updated valuation work. Analyst Commentary Analysts are reassessing Lifecare after the latest valuation update, and the revised inputs around growth, margins, discount rate, and future P/E are shaping both the optimistic and cautious views.Narrative Update • May 10
LIFE: Future Regulatory Clearance On CGM Implant Will Support Repricing Potential
Analysts have lifted their price target on Lifecare to NOK 0.65 per share, citing a slightly lower discount rate, a modestly higher forecast profit margin, and a reduced forward P/E assumption that together support a more efficient earnings profile at the same fair value level. Analyst Commentary Recent research commentary on Lifecare centers on how the revised price target aligns with updated assumptions for profitability, discount rates, and forward P/E.Narrative Update • Apr 20
LIFE: Future Regulatory Progress On CGM Implant Will Drive Repricing Potential
The analyst price target for Lifecare has been revised to reflect a steady fair value of NOK 0.65. This incorporates slightly updated assumptions for the discount rate, profit margin, and forward P/E, as analysts highlight supportive research on comparable tech-enabled insurance platforms and their large, underpenetrated markets.Narrative Update • Apr 04
LIFE: Future Regulatory Progress And Commercial Execution Will Drive Repricing Potential
Analysts have nudged up the Lifecare price target to NOK 0.65, citing a lower discount rate and slightly refined long term P/E assumptions while maintaining their fair value estimate. Analyst Commentary Analysts looking at Lifecare’s revised price target are framing it in the context of how similar high growth, tech enabled models in other parts of the health and insurance space are being valued.Narrative Update • Mar 20
LIFE: Future Regulatory And Clinical Milestones Will Drive Repricing Potential
The analyst price target for Lifecare has been raised by NOK 1, reflecting updated assumptions around a higher discount rate, more measured revenue growth at 51.30% and a slightly lower projected profit margin of 19.61%. The valuation still applies a forward P/E of 4.39x that analysts see as supported by improving unit economics and technology driven operating efficiencies similar to those recently highlighted across the life insurance peer group.Narrative Update • Mar 04
LIFE: Future Execution On CGM Milestones Will Drive Repricing Potential
Analysts have revised their price target on Lifecare to NOK0.65 from NOK19, reflecting updated assumptions around a higher discount rate, more moderate revenue growth, a slightly stronger profit margin profile, and a lower future P/E multiple. Analyst Commentary While the recent Lifecare price target revision to NOK0.65 signals a more cautious stance, Street research on a comparable digital life insurance player, Ethos, offers a useful reference point for how analysts think about valuation, growth, and execution in this type of business model.Narrative Update • Aug 22
TTP Collaboration And Sensor Chemistry Will Streamline Manufacturing
Despite a sharp increase in Lifecare’s consensus revenue growth forecast and a notable drop in future P/E, analysts have significantly lowered the fair value estimate from NOK24.00 to NOK19.00. What's in the News Lifecare received conditional ethics approval from Norway’s REK for its first-in-human trial of the implantable GCM (Continuous Glucose Monitoring) sensor, with final regulatory clearance pending from the Norwegian Medicines Agency.
New Narrative • Apr 17
TTP Collaboration And Sensor Chemistry Will Streamline Manufacturing
Strategic partnerships and technological advancements could significantly enhance market position and revenue growth through improved product efficiency and expanded market access.Analysis Article • Sep 13
We Think Lifecare (OB:LIFE) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Apr 30
We're Interested To See How Lifecare (OB:LIFE) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholder Returns
| LIFE | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | -10.7% | -0.04% | 0.2% |
| 1Y | -95.4% | -23.0% | 18.3% |
Return vs Industry: LIFE underperformed the Norwegian Medical Equipment industry which returned -23% over the past year.
Return vs Market: LIFE underperformed the Norwegian Market which returned 18.3% over the past year.
Price Volatility
| LIFE volatility | |
|---|---|
| LIFE Average Weekly Movement | 23.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.4% |
| 10% least volatile stocks in NO Market | 3.2% |
Stable Share Price: LIFE's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: LIFE's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 25 | Joacim Holter | lifecare.no |
Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway.
Lifecare ASA Fundamentals Summary
| LIFE fundamental statistics | |
|---|---|
| Market cap | NOK 87.95m |
| Earnings (TTM) | -NOK 136.09m |
| Revenue (TTM) | NOK 7.42m |
11.9x
P/S Ratio-0.6x
P/E RatioIs LIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIFE income statement (TTM) | |
|---|---|
| Revenue | NOK 7.42m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 7.42m |
| Other Expenses | NOK 143.51m |
| Earnings | -NOK 136.09m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 19, 2026
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,835.15% |
| Debt/Equity Ratio | 0% |
How did LIFE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 03:47 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lifecare ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |
| Ludvig Svensson | DNB Carnegie Commissioned Research |